
Wolfgang D Schmitt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6161747/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer Journal of Clinical Oncology, 2022, 40, 581-581.	1.6	3
2	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	7.0	27
3	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 2021, 13, 1076.	3.7	5
4	Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. Cancers, 2021, 13, 1512.	3.7	14
5	Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapyâ<†. Annals of Oncology, 2021, 32, 500-511.	1.2	9
6	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
7	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	10.7	248
8	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics, 2021, 13, 184.	4.1	2
9	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study. European Journal of Cancer, 2019, 114, 76-88.	2.8	37
10	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto. Journal of Clinical Oncology, 2019, 37, 2226-2234.	1.6	95
11	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clinical Cancer Research, 2019, 25, 3986-3995.	7.0	32
12	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Human Pathology, 2019, 85, 299-308.	2.0	24
13	MALDIâ€Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. Proteomics - Clinical Applications, 2019, 13, e1700181.	1.6	45
14	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	5.3	23
15	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	10.7	1,327
16	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC) Journal of Clinical Oncology, 2018, 36, 104-104.	1.6	43
17	Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1) Journal of Clinical Oncology, 2018, 36, 527-527.	1.6	0
18	Abstract S1-09: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients. , 2017, , .		12

#	Article	IF	CITATIONS
19	A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC) Journal of Clinical Oncology, 2017, 35, 3062-3062.	1.6	11
20	Ki67 as a prognostic factor in low grade serous ovarian cancer (LGSOC): A retrospective analysis of the Tumor Bank Ovarian Cancer (TOC) Journal of Clinical Oncology, 2017, 35, 5562-5562.	1.6	1
21	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget, 2017, 8, 102912-102922.	1.8	57
22	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5747-5754.	7.0	158
23	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 345-356.	10.7	316
24	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. Cancer Research, 2016, 76, 796-804.	0.9	74
25	Role of <i>TP53</i> mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698.	1.8	50
26	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers. Journal of Clinical Oncology, 2015, 33, 983-991.	1.6	863
27	Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research, 2015, 21, 3651-3657.	7.0	85
28	RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Research and Treatment, 2014, 145, 307-315.	2.5	59
29	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Annals of Oncology, 2013, 24, 2786-2793.	1.2	181
30	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4521-4531.	7.0	137
31	Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). , 2013, , .		16
32	Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization. PLoS ONE, 2012, 7, e51862.	2.5	983
33	CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	3.1	37
34	Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies. Journal of Clinical Oncology, 2010, 28, 3264-3270.	1.6	56
35	Small polydispersed circular DNA contains strains of mobile genetic elements and occurs more frequently in permanent cell lines of malignant tumors than in normal lymphocytes. Oncology Reports, 2009, , .	2.6	11
36	Ribozyme to TGF-β1 mRNA abrogates immunosuppressive effects of human colorectal adenocarcinoma HRT-18 cells in vitro and in vivo. International Journal of Oncology, 2009, 35, 901-8.	3.3	0

WOLFGANG D SCHMITT

#	Article	IF	CITATIONS
37	Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. International Journal of Oncology, 2009, 36, .	3.3	17
38	Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene, 2007, 26, 7584-7589.	5.9	101
39	Transposable elements – Is there a link between evolution and cancer?. Medical Hypotheses, 2006, 66, 580-591.	1.5	10
40	Ezrin Promotes Ovarian Carcinoma Cell Invasion and Its Retained Expression Predicts Poor Prognosis in Ovarian Carcinoma. International Journal of Gynecological Pathology, 2006, 25, 121-130.	1.4	59
41	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Modern Pathology, 2006, 19, 581-587.	5.5	52
42	Influence of Various Cytokines on Adhesion and Migration of the Colorectal Adenocarcinoma Cell Line HRT-18. Oncology, 2005, 68, 33-39.	1.9	6
43	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. American Journal of Pathology, 2005, 167, 879-885.	3.8	27
44	Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 456-464.	2.8	61
45	Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. British Journal of Cancer, 2002, 86, 1310-1315.	6.4	60
46	Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. International Journal of Cancer, 2002, 102, 507-513.	5.1	106